Tumor-induced lymphangiogenesis: A target for cancer therapy?

Journal of Biotechnology

Volumn 124, Issue 1, 2006, Pages 224-241

  Thiele, Wilko ^a   Sleeman, Jonathan P ^a  

^a KARLSRUHE INSTITUTE OF TECHNOLOGY   (Germany)

Author keywords

Lymphangiogenesis; Metastasis; VEGF C; VEGF D; VEGFR 3

Indexed keywords

BIOLOGICAL ORGANS; BIOTECHNOLOGY; BLOOD; DISEASES; DRUG THERAPY; PHYSIOLOGICAL MODELS;

LYMPHANGIOGENESIS; METASTASIS; THERAPEUTIC AGENTS; VEGF-C; VEGF-D; VEGFR-3;

TUMORS;

ANGIOGENESIS INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3; VASCULOTROPIN RECEPTOR 3 INHIBITOR;

BLOOD TOXICITY; CANCER INHIBITION; CANCER INVASION; CANCER PREVENTION; CANCER THERAPY; CARCINOGENESIS; CORRELATIONAL STUDY; DRUG POTENCY; DRUG TARGETING; EDEMA; HUMAN; LYMPH NODE METASTASIS; LYMPH VESSEL; LYMPHANGIOGENESIS; MOLECULAR BIOLOGY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; REVIEW; TISSUE DISTRIBUTION; TUMOR CELL; TUMOR GROWTH; TUMOR VASCULARIZATION; UPREGULATION;

ANIMALS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPH NODES; LYMPHANGIOGENESIS; LYMPHATIC METASTASIS; NEOPLASMS; VASCULAR ENDOTHELIAL GROWTH FACTOR C; VASCULAR ENDOTHELIAL GROWTH FACTOR D; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

ANIMALIA;

EID: 33744526916     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2006.01.007     Document Type: Review

References (159)

1. Achen M.G., Jeltsch M., Kukk E., Makinen T., Vitali A., Wilks A.F., Alitalo K., and Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. U.S.A. 95 2 (1998) 548-553
2. Achen M.G., Roufail S., Domagala T., Catimel B., Nice E.C., Geleick D.M., Murphy R., Scott A.M., Caesar C., Makinen T., Alitalo K., and Stacker S.A. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem. 267 9 (2000) 2505-2515
3. Akagi K., Ikeda Y., Miyazaki M., Abe T., Kinoshita J., Maehara Y., and Sugimachi K. Vascular endothelial growth factor-C (VEGF-C) expression in human colorectal cancer tissues. Br. J. Cancer 83 7 (2000) 887-891
4. Amioka T., Kitadai Y., Tanaka S., Haruma K., Yoshihara M., Yasui W., and Chayama K. Vascular endothelial growth factor-C expression predicts lymph node metastasis of human gastric carcinomas invading the submucosa. Eur. J. Cancer 38 10 (2002) 1413-1419
5. Arinaga M., Noguchi T., Takeno S., Chujo M., Miura T., and Uchida Y. Clinical significance of vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 in patients with non-small cell lung carcinoma. Cancer 97 2 (2003) 457-464
6. Baluk P., Tammela T., Ator E., Lyubynska N., Achen M.G., Hicklin D.J., Jeltsch M., Petrova T.V., Pytowski B., Stacker S., Ylä-Herttuala S., Jackson D.G., Alitalo K., and McDonald D.M. Pathogenesis of persistent lymphatic vessel hyperplasia in chronic airway inflammation. J. Clin. Invest. 115 2 (2005) 247-257
7. Beasley N.J., Prevo R., Banerji S., Leek R.D., Moore J., van Trappen P., Cox G., Harris A.L., and Jackson D.G. Intratumoral lymphangiogenesis and lymph node metastasis in head and neck cancer. Cancer Res. 62 5 (2002) 1315-1320
8. Bono P., Wasenius V., Heikkilä P., Lundin J., Jackson D.G., and Joensuu H. High LYVE-1-positive lymphatic vessel numbers are associated with poor outcome in breast cancer. Clin. Cancer Res. 10 21 (2004) 7144-7149
9. Birner P., Schindl M., Obermair A., Plank C., Breitenecker G., Kowalski H., and Oberhuber G. Lymphatic microvessel density in epithelial ovarian cancer: its impact on prognosis. Anticancer Res. 20 5A (2000) 2981-2985
10. Bjorndahl M.A., Cao R., Burton J.B., Brakenhielm E., Religa P., Galter D., Wu L., and Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 65 (2005) 9261-9268
11. Bunone G., Vigneri P., Mariani L., Buto S., Collini P., Pilotti S., Pierotti M.A., and Bongarzone I. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am. J. Pathol. 155 6 (1999) 1967-1976
12. Byeon J.S., Jung H.Y., Lee Y.J., Lee D., Lee G.H., Myung S.J., Yang S.K., Hong W.S., Kim J.H., Min Y.I., and Kim J.S. Clinicopathological significance of vascular endothelial growth factor-C and cyclooxygenase-2 in esophageal squamous cell carcinoma. J. Gastroenterol. Hepatol. 19 6 (2004) 648-654
13. Cao Y., Linden P., Farnebo J., Cao R., Eriksson A., Kumar V., Qi J.H., Claesson-Welsh L., and Alitalo K. Vascular endothelial growth factor C induces angiogenesis in vivo. Proc. Natl Acad. Sci. U.S.A. 95 24 (1998) 14389-14394
14. Cao R., Bjorndahl M.A., Religa P., Clasper S., Garvin S., Galter D., Meister B., Ikomi F., Tritsaris K., Dissing S., Ohhashi T., Jackson D.G., and Cao Y. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 6 4 (2004) 333-345
15. Carreira C.M., Nasser S.M., di Tomaso E., Padera T.P., Boucher Y., Tomarev S.I., and Jain R.K. LYVE-1 is not restricted to the lymph vessels: expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res. 61 (2001) 8079-8084
16. Chang L.K., Garcia-Cardena G., Farnebo F., Fannon M., Chen E.J., Butterfield C., Moses M.A., Mulligan R.C., Folkman J., and Kaipainen A. Dose-dependent response of FGF-2 for lymphangiogenesis. Proc. Natl. Acad. Sci. U.S.A. 10 101 (32) (2004) 11658-11663
17. Choi W.W., Lewis M.M., Lawson D., Yin-Goen Q., Birdsong G.G., Cotsonis G.A., Cohen C., and Young A.N. Angiogenic and lymphangiogenic microvessel density in breast carcinoma: correlation with clinicopathologic parameters and VEGF-family gene expression. Mod. Pathol. 18 1 (2005) 143-152
18. Currie M.J., Hanrahan V., Gunningham S.P., Morrin H.R., Frampton C., Han C., Robinson B.A., and Fox S.B. Expression of vascular endothelial growth factor D is associated with hypoxia inducible factor (HIF-1alpha) and the HIF-1alpha target gene DEC1, but not lymph node metastasis in primary human breast carcinomas. J. Clin. Pathol. 57 8 (2004) 829-834
19. Dadras S.S., Paul T., Bertoncini J., Brown L.F., Muzikansky A., Jackson D.G., Ellwanger U., Garbe C., Mihm M.C., and Detmar M. Tumor lymphangiogenesis: a novel prognostic indicator for cutaneous melanoma metastasis and survival. Am. J. Pathol. 162 6 (2003) 1951-1960
20. Duff S.E., Li C., Jeziorska M., Kumar S., Saunders M.P., Sherlock D., O'Dwyer S.T., and Jayson G.C. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br. J. Cancer 89 3 (2003) 426-430
21. Dumont D.J., Jussila L., Taipale J., Lymboussaki A., Mustonen T., Pajusola K., Breitman M., and Alitalo K. Cardiovascular failure in mouse embryos deficient in VEGF receptor-3. Science 282 5390 (1998) 946-949
22. Fernandez Pujol B., Lucibello F.C., Zuzarte M., Lutjens P., Muller R., and Havemann K. Dendritic cells derived from peripheral monocytes express endothelial markers and in the presence of angiogenic growth factors differentiate into endothelial-like cells. Eur. J. Cell Biol. 80 1 (2001) 99-110
23. Fitz L.J., Morris J.C., Towler P., Long A., Burgess P., Greco R., Wang J., Gassaway R., Nickbarg E., Kovacic S., Ciarletta A., Giannotti J., Finnerty H., Zollner R., Beier D.R., Leak L.V., Turner K.J., and Wood C.R. Characterization of murine Flt4 ligand/VEGF-C. Oncogene 15 5 (1997) 613-618
24. Franchi A., Gallo O., Massi D., Baroni G., and Santucci M. Tumor lymphangiogenesis in head and neck squamous cell carcinoma: a morphometric study with clinical correlations. Cancer 101 5 (2004) 973-978
25. Fujimoto J., Toyoki H., Sato E., Sakaguchi H., and Tamaya T. Clinical implication of expression of vascular endothelial growth factor-C in metastatic lymph nodes of uterine cervical cancers. Br. J. Cancer 91 3 (2004) 466-469
26. Funaki H., Nishimura G., Harada S., Ninomiya I., Terada I., Fushida S., Tani T., Fujimura T., Kayahara M., Shimizu K., Ohta T., and Miwa K. Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma. Oncology 64 4 (2003) 416-422
27. Furudoi A., Tanaka S., Haruma K., Kitadai Y., Yoshihara M., Chayama K., and Shimamoto F. Clinical significance of vascular endothelial growth factor C expression and angiogenesis at the deepest invasive site of advanced colorectal carcinoma. Oncology 62 2 (2002) 157-166
28. George M.L., Tutton M.G., Janssen F., Arnaout A., Abulafi A.M., Eccles S.A., and Swift R.I. VEGF-A, VEGF-C, and VEGF-D in colorectal cancer progression. Neoplasia 3 5 (2001) 420-427
29. Giorgadze T.A., Zhang P.J., Pasha T., Coogan P.S., Acs G., Elder D.E., and Xu X. Lymphatic vessel density is significantly increased in melanoma. J. Cutan Pathol. 31 10 (2004) 672-677
30. Giorgadze T.A., Baloch Z.W., Pasha T., Zhang P.J., and Livolsi V.A. Lymphatic and blood vessel density in the follicular patterned lesions of thyroid. Mod. Pathol. 18 11 (2005) 1424-1431
31. Gunningham S.P., Currie M.J., Han C., Robinson B.A., Scott P.A., Harris A.L., and Fox S.B. The short form of the alternatively spliced flt-4 but not its ligand vascular endothelial growth factor C is related to lymph node metastasis in human breast cancers. Clin. Cancer Res. 6 11 (2000) 4278-4286
32. Guyton A., and Hall J. Textbook of Medical Physiology. ninth ed. (1996), W.B. Saunders Company, Philadelphia
33. Hall F.T., Freeman J.L., Asa S.L., Jackson D.G., and Beasley N.J. Intratumoral lymphatics and lymph node metastases in papillary thyroid carcinoma. Arch. Otolaryngol. Head Neck Surg. 129 7 (2003) 716-719
34. Hamada K., Oike Y., Takakura N., Ito Y., Jussila L., Dumont D.J., Alitalo K., and Suda T. VEGF-C signaling pathways through VEGFR-2 and VEGFR-3 in vasculoangiogenesis and hematopoiesis. Blood 96 12 (2000) 3793-3800
35. Hamrah P., Chen L., Cursiefen C., Zhang Q., Joyce N.C., and Dana M.R. Expression of vascular endothelial growth factor receptor-3 (VEGFR-3). on monocytic bone marrow-derived cells in the conjunctiva. Exp. Eye Res. 79 4 (2004) 553-561
36. Hamrah P., Chen L., Zhang Q., and Dana M.R. Novel expression of vascular endothelial growth factor receptor (VEGFR)-3 and VEGF-C on corneal dendritic cells. Am. J. Pathol. 163 1 (2003) 57-68
37. Hanrahan V., Currie M.J., Gunningham S.P., Morrin H.R., Scott P.A., Robinson B.A., and Fox S.B. The angiogenic switch for vascular endothelial growth factor (VEGF)-A, VEGF-B, VEGF-C, and VEGF-D in the adenoma-carcinoma sequence during colorectal cancer progression. J. Pathol. 200 2 (2003) 183-194
38. Hashimoto I., Kodama J., Seki N., Hongo A., Yoshinouchi M., Okuda H., and Kudo T. Vascular endothelial growth factor-C expression and its relationship to pelvic lymph node status in invasive cervical cancer. Br. J. Cancer 85 1 (2001) 93-97
39. He Y., Kozaki K., Karpanen T., Koshikawa K., Yla-Herttuala S., Takahashi T., and Alitalo K. Suppression of tumor lymphangiogenesis and lymph node metastasis by blocking vascular endothelial growth factor receptor 3 signaling. J. Natl. Cancer Inst. 94 (2002) 819-825
40. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., and Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 65 11 (2005) 4739-4746
41. Hirai M., Nakagawara A., Oosaki T., Hayashi Y., Hirono M., and Yoshihara T. Expression of vascular endothelial growth factors (VEGF-A/VEGF-1 and VEGF-C/VEGF-2) in postmenopausal uterine endometrial carcinoma. Gynecol. Oncol. 80 2 (2001) 181-188
42. Hirakawa S., Kodama S., Kunstfeld R., Kajiya K., Brown L.F., and Detmar M. VEGF-A induces tumor and sentinel lymph node lymphangiogenesis and promotes lymphatic metastasis. J. Exp. Med. 201 (2005) 1089-1099
43. Hoar F.J., Chaudhri S., Wadley M.S., and Stonelake P.S. Co-expression of vascular endothelial growth factor C (VEGF-C) and c-erbB2 in human breast carcinoma. Eur. J. Cancer 39 12 (2003) 1698-1703
44. Hong Y.K., Harvey N., Noh Y.H., Schacht V., Hirakawa S., Detmar M., and Oliver G. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev. Dyn. 225 3 (2002) 351-357
45. Huang X.Z., Wu J.F., Ferrando R., Lee J.H., Wang Y.L., Farese Jr. R.V., and Sheppard D. Fatal bilateral chylothorax in mice lacking the integrin alpha9beta1. Mol. Cell Biol. 20 14 (2000) 5208-5215
46. Irjala H., Alanen K., Grenman R., Heikkila P., Joensuu H., and Jalkanen S. Mannose receptor (MR) and common lymphatic endothelial and vascular endothelial receptor (CLEVER)-1 direct the binding of cancer cells to the lymph vessel endothelium. Cancer Res. 63 15 (2003) 4671-4676
47. Ishikawa M., Kitayama J., Kazama S., and Nagawa H. Expression of vascular endothelial growth factor C and D (VEGF-C and -D) is an important risk factor for lymphatic metastasis in undifferentiated early gastric carcinoma. Jpn. J. Clin. Oncol. 33 1 (2003) 21-27
48. Ishikawa M., Kitayama J., Kazama S., and Nagawa H. Expression of vascular endothelial growth factor (VEGF)-C in preoperative biopsy specimens and metastatic foci of regional lymph nodes in submucosal gastric carcinoma. World J. Surg. Oncol. 3 1 (2005) 2
49. Jackson D.G. Biology of the lymphatic marker LYVE-1 and applications in research into lymphatic trafficking and lymphangiogenesis. APMIS 112 7-8 (2004) 526-538
50. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R.K., and Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 276 5317 (1997) 1423-1425
51. Jennbacken K., Vallbo C., Wang W., and Damber J.E. Expression of vascular endothelial growth factor C (VEGF-C) and VEGF receptor-3 in human prostate cancer is associated with regional lymph node metastasis. Prostate 65 2 (2005) 110-116
52. Jia Y.T., Li Z.X., He Y.T., Liang W., Yang H.C., and Ma H.J. Expression of vascular endothelial growth factor-C and the relationship between lymphangiogenesis and lymphatic metastasis in colorectal cancer. World J. Gastroenterol. 10 22 (2004) 3261-3263
53. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., and Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 15 2 (1996) 290-298
54. Joukov V., Sorsa T., Kumar V., Jeltsch M., Claesson-Welsh L., Cao Y., Saksela O., Kalkkinen N., and Alitalo K. Proteolytic processing regulates receptor specificity and activity of VEGF-C. EMBO J. 16 13 (1997) 3898-3911
55. Kabashima A., Maehara Y., Kakeji Y., and Sugimachi K. Overexpression of vascular endothelial growth factor C is related to lymphogenous metastasis in early gastric carcinoma. Oncology 60 2 (2001) 146-150
56. Kajita T., Ohta Y., Kimura K., Tamura M., Tanaka Y., Tsunezuka Y., Oda M., Sasaki T., and Watanabe G. The expression of vascular endothelial growth factor C and its receptors in non-small cell lung cancer. Br. J. Cancer 85 2 (2001) 255-260
57. Kajiya K., Hirakawa S., Ma B., Drinnenberg I., and Detmar M. Hepatocyte growth factor promotes lymphatic vessel formation and function. EMBO J. 24 (2005) 2885-2895
58. Karkkainen M.J., Haiko P., Sainio K., Partanen J., Taipale J., Petrova T.V., Jeltsch M., Jackson D.G., Talikka M., Rauvala H., Betsholtz C., and Alitalo K. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat. Immunol. 5 1 (2004) 74-80
59. Karpanen T., Egeblad M., Karkkainen M.J., Kubo H., Yla-Herttuala S., Jaattela M., and Alitalo K. Vascular endothelial growth factor C promotes tumor lymphangiogenesis and intralymphatic tumor growth. Cancer Res. 61 (2001) 1786-1790
60. Kaushal V., Mukunyadzi P., Dennis R.A., Siegel E.R., Johnson D.E., and Kohli M. Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease. Clin. Cancer Res. 11 2 Pt 1 (2005) 584-593
61. Kawakami M., Furuhata T., Kimura Y., Yamaguchi K., Hata F., Sasaki K., and Hirata K. Quantification of vascular endothelial growth factor-C and its receptor-3 messenger RNA with real-time quantitative polymerase chain reaction as a predictor of lymph node metastasis in human colorectal cancer. Surgery 133 3 (2003) 300-308
62. Kawakami M., Furuhata T., Kimura Y., Yamaguchi K., Hata F., Sasaki K., and Hirata K. Expression analysis of vascular endothelial growth factors and their relationships to lymph node metastasis in human colorectal cancer. J. Exp. Clin. Cancer Res. 22 2 (2003) 229-237
63. Kazama S., Kitayama J., Watanabe T., and Nagawa H. Expression pattern of vascular endothelial growth factor-C in human colorectal normal mucosa and neoplastic mucosa. Hepatogastroenterology 51 56 (2004) 391-395
64. Kimura Y., Watanabe M., Ohga T., Saeki H., Kakeji Y., Baba H., and Maehara Y. Vascular endothelial growth factor C expression correlates with lymphatic involvement and poor prognosis in patients with esophageal squamous cell carcinoma. Oncol Rep. 10 6 (2003) 1747-1751
65. Kinoshita J., Kitamura K., Kabashima A., Saeki H., Tanaka S., and Sugimachi K. Clinical significance of vascular endothelial growth factor-C (VEGF-C) in breast cancer. Breast Cancer Res. Treat. 66 2 (2001) 159-164
66. Kirkin V., Mazitschek R., Krishnan J., Steffen A., Waltenberger J., Pepper M.S., Giannis A., and Sleeman J.P. Characterization of indolinones which preferentially inhibit VEGF-C- and VEGF-D-induced activation of VEGFR-3 rather than VEGFR-2. Eur. J. Biochem. 268 (2001) 5530-5540
67. Kirkin V., Thiele W., Baumann P., Mazitschek R., Rohde K., Fellbrich G., Weich H., Waltenberger J., Giannis A., and Sleeman J.P. MAZ51, an indolinone that inhibits endothelial cell and tumor cell growth in vitro, suppresses tumor growth in vivo. Int. J. Cancer 112 6 (2004) 986-993
68. Kishimoto K., Sasaki A., Yoshihama Y., Mese H., Tsukamoto G., and Matsumura T. Expression of vascular endothelial growth factor-C predicts regional lymph node metastasis in early oral squamous cell carcinoma. Oral Oncol. 39 4 (2003) 391-396
69. Kitadai Y., Amioka T., Haruma K., Tanaka S., Yoshihara M., Sumii K., Matsutani N., Yasui W., and Chayama K. Clinicopathological significance of vascular endothelial growth factor (VEGF)-C in human esophageal squamous cell carcinomas. Int. J. Cancer 93 5 (2001) 662-666
70. Kitadai Y., Kodama M., Cho S., Kuroda T., Ochiumi T., Kimura S., Tanaka S., Matsumura S., Yasui W., and Chayama K. Quantitative analysis of lymphangiogenic markers for predicting metastasis of human gastric carcinoma to lymph nodes. Int. J. Cancer 115 3 (2005) 388-392
71. Koyama Y., Kaneko K., Akazawa K., Kanbayashi C., Kanda T., and Hatakeyama K. Vascular endothelial growth factor-C and vascular endothelial growth factor-d messenger RNA expression in breast cancer: association with lymph node metastasis. Breast Cancer 4 5 (2003) 354-360
72. Komuro H., Kaneko S., Kaneko M., and Nakanishi Y. Expression of angiogenic factors and tumor progression in human neuroblastoma. J. Cancer Res. Clin. Oncol. 127 12 (2001) 739-743
73. Krishnan J., Kirkin V., Steffen A., Hegen M., Weih D., Tomarev S., Wilting J., and Sleeman J.P. Differential in vivo and in vitro expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in tumors and its relationship to lymphatic metastasis in immunocompetent rats. Cancer Res. 63 (2003) 713-722
74. Kubo H., Fujiwara T., Jussila L., Hashi H., Ogawa M., Shimizu K., Awane M., Sakai Y., Takabayashi A., Alitalo K., Yamaoka Y., and Nishikawa S.I. Involvement of vascular endothelial growth factor receptor-3 in maintenance of integrity of endothelial cell lining during tumor angiogenesis. Blood 96 2 (2000) 546-553
75. Kubo H., Cao R., Brakenhielm E., Makinen T., Cao Y., and Alitalo K. Blockade of vascular endothelial growth factor receptor-3 signaling inhibits fibroblast growth factor-2-induced lymphangiogenesis in mouse cornea. Proc. Natl. Acad. Sci. U.S.A. 25 99 (13) (2002) 8868-8873
76. Kurahara H., Takao S., Maemura K., Shinchi H., Natsugoe S., and Aikou T. Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis. Clin. Cancer Res. 10 24 (2004) 8413-8420
77. Kyzas P.A., Geleff S., Batistatou A., Agnantis N.J., and Stefanou D. Evidence for lymphangiogenesis and its prognostic implications in head and neck squamous cell carcinoma. J. Pathol. 206 2 (2005) 170-177
78. Lee J., Gray A., Yuan J., Luoh S.M., Avraham H., and Wood W.I. Vascular endothelial growth factor-related protein: a ligand and specific activator of the tyrosine kinase receptor Flt4. Proc. Natl. Acad. Sci. U.S.A. 93 5 (1996) 1988-1992
79. Li Q., Dong X., Gu W., Qiu X., and Wang E. Clinical significance of co-expression of VEGF-C and VEGFR-3 in non-small cell lung cancer. Chin. Med. J. (Engl.) 116 5 (2003) 727-730
80. Lin B., Podar K., Gupta D., Tai Y.T., Li S., Weller E., Hideshima T., Lentzsch S., Davies F., Li C., Weisberg E., Schlossman R.L., Richardson P.G., Griffin J.D., Wood J., Munshi N.C., and Anderson K.C. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 62 17 (2002) 5019-5026
81. Liu X.E., Sun X.D., and Wu J.M. Expression and significance of VEGF-C and FLT-4 in gastric cancer. World J. Gastroenterol. 10 3 (2004) 352-355
82. Maeda K., Yashiro M., Nishihara T., Nishiguchi Y., Sawai M., Uchima K., Onoda N., Ohira M., Ishikawa T., and Hirakawa K. Correlation between vascular endothelial growth factor C expression and lymph node metastasis in T1 carcinoma of the colon and rectum. Surg. Today 33 10 (2003) 736-739
83. Makinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., Yla-Herttuala S., and Alitalo K. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 7 2 (2001) 199-205
84. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D.G., Orci L., Alitalo K., Christofori G., and Pepper M.S. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 20 4 (2001) 672-682
85. Mattila M.M., Ruohola J.K., Karpanen T., Jackson D.G., Alitalo K., and Harkonen P.L. VEGF-C induced lymphangiogenesis is associated with lymph node metastasis in orthotopic MCF-7 tumors. Int. J. Cancer 98 (2002) 946-951
86. Matzkin H., Patel J.P., Altwein J.E., and Soloway M.S. Stage T1A carcinoma of prostate. Urology 43 (1994) 11-21
87. Marconcini L., Marchio S., Morbidelli L., Cartocci E., Albini A., Ziche M., Bussolino F., and Oliviero S. c-fos-induced growth factor/vascular endothelial growth factor D induces angiogenesis in vivo and in vitro. Proc. Natl. Acad. Sci. U.S.A. 96 17 (1999) 9671-9676
88. Maula S.M., Luukkaa M., Grenman R., Jackson D., Jalkanen S., and Ristamaki R. Intratumoral lymphatics are essential for the metastatic spread and prognosis in squamous cell carcinomas of the head and neck region. Cancer Res. 63 8 (2003) 1920-1926
89. Morisada T., Oike Y., Yamada Y., Urano T., Akao M., Kubota Y., Maekawa H., Kimura Y., Ohmura M., Miyamoto T., Nozawa S., Koh G.Y., Alitalo K., and Suda T. Angiopoietin-1 promotes LYVE-1-positive lymphatic vessel formation. Blood 105 12 (2005) 4649-4656
90. Nakamura Y., Yasuoka H., Tsujimoto M., Yang Q., Tsukiyama A., Imabun S., Nakahara M., Nakao K., Nakamura M., Mori I., and Kakudo K. Clinicopathological significance of vascular endothelial growth factor-C in breast carcinoma with long-term follow-up. Mod. Pathol. 16 4 (2003) 309-314
91. Nakamura Y., Yasuoka H., Tsujimoto M., Yang Q., Imabun S., Nakahara M., Nakao K., Nakamura M., Mori I., and Kakudo K. Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up. Clin. Cancer Res. 9 2 (2003) 716-721
92. Nakamura Y., Yasuoka H., Tsujimoto M., Imabun S., Nakahara M., Nakao K., Nakamura M., Mori I., and Kakudo K. Lymph vessel density correlates with nodal status, VEGF-C expression, and prognosis in breast cancer. Breast Cancer Res. Treat. 91 2 (2005) 125-132
93. Nakashima T., Kondoh S., Kitoh H., Ozawa H., Okita S., Harada T., Shiraishi K., Ryozawa S., and Okita K. Vascular endothelial growth factor-C expression in human gallbladder cancer and its relationship to lymph node metastasis. Int. J. Mol. Med. 11 1 (2003) 33-39
94. Neuchrist C., Erovic B.M., Handisurya A., Fischer M.B., Steiner G.E., Hollemann D., Gedlicka C., Saaristo A., and Burian M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 3 expression in squamous cell carcinomas of the head and neck. Head Neck 25 6 (2003) 464-474
95. Niki T., Iba S., Tokunou M., Yamada T., Matsuno Y., and Hirohashi S. Expression of vascular endothelial growth factors A, B, C, and D and their relationships to lymph node status in lung adenocarcinoma. Clin. Cancer Res. 6 6 (2000) 2431-2439
96. Nishida N., Yano H., Komai K., Nishida T., Kamura T., and Kojiro M. Vascular endothelial growth factor C and vascular endothelial growth factor receptor 2 are related closely to the prognosis of patients with ovarian carcinoma. Cancer 101 6 (2004) 1364-1374
97. Noguchi T., Takeno S., Shibata T., Uchida Y., Yokoyama S., and Muller W. VEGF-C expression correlates with histological differentiation and metastasis in squamous cell carcinoma of the esophagus. Oncol. Rep. 9 5 (2002) 995-999
98. O-Charoenrat P., Rhys-Evans P., and Eccles S.A. Expression of vascular endothelial growth factor family members in head and neck squamous cell carcinoma correlates with lymph node metastasis. Cancer 92 3 (2001) 556-568
99. Ogawa E., Takenaka K., Yanagihara K., Kurozumi M., Manabe T., Wada H., and Tanaka F. Clinical significance of VEGF-C status in tumour cells and stromal macrophages in non-small cell lung cancer patients. Br. J. Cancer 91 3 (2004) 498-503
100. Oh S.J., Jeltsch M.M., Birkenhager R., McCarthy J.E., Weich H.A., Christ B., Alitalo K., and Wilting J. VEGF and VEGF-C: specific induction of angiogenesis and lymphangiogenesis in the differentiated avian chorioallantoic membrane. Dev. Biol. 188 1 (1997) 96-109
101. Ohta Y., Nozawa H., Tanaka Y., Oda M., and Watanabe Y. Increased vascular endothelial growth factor and vascular endothelial growth factor-C and decreased NM23 expression associated with microdissemination in the lymph nodes in stage I non-small cell lung cancer. J. Thorac. Cardiovasc. Surg. 119 4 (2000) 804-813
102. Onogawa S., Kitadai Y., Tanaka S., Kuwai T., Kimura S., and Chayama K. Expression of VEGF-C and VEGF-D at the invasive edge correlates with lymph node metastasis and prognosis of patients with colorectal carcinoma. Cancer Sci. 95 1 (2004) 32-39
103. Paavonen K., Puolakkainen P., Jussila L., Jahkola T., and Alitalo K. Vascular endothelial growth factor receptor-3 in lymphangiogenesis in wound healing. Am. J. Pathol. 156 5 (2000) 1499-1504
104. Padera T.P., Kadambi A., di Tomaso E., Carreira C.M., Brown E.B., Boucher Y., Choi N.C., Mathisen D., Wain J., Mark E.J., Munn L.L., and Jain R.K. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296 5574 (2002) 1883-1886
105. Pepper M.S. Lymphangiogenesis and tumor metastasis: myth or reality?. Clin. Cancer Res. 7 (2001) 462-468
106. Persaud K., Tille J.C., Liu M., Zhu Z., Jimenez X., Pereira D.S., Miao H.Q., Brennan L.A., Witte L., Pepper M.S., and Pytowski B. Involvement of the VEGF receptor 3 in tubular morphogenesis demonstrated with a human anti-human VEGFR-3 monoclonal antibody that antagonizes receptor activation by VEGF-C. J. Cell Sci. 117 Pt 13 (2004) 2745-2756
107. Petrova T.V., Makinen T., Makela T.P., Saarela J., Virtanen I., Ferrell R.E., Finegold D.N., Kerjaschki D., Yla-Herttuala S., and Alitalo K. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 21 17 (2002 Sep 2) 4593-4599
108. Rubbia-Brandt L., Terris B., Giostra E., Dousset B., Morel P., and Pepper M.S. Lymphatic vessel density and vascular endothelial growth factor-C expression correlate with malignant behavior in human pancreatic endocrine tumors. Clin. Cancer Res. 10 20 (2004) 6919-6928
109. Ruggeri B., Singh J., Gingrich D., Angeles T., Albom M., Yang S., Chang H., Robinson C., Hunter K., Dobrzanski P., Jones-Bolin S., Pritchard S., Aimone L., Klein-Szanto A., Herbert J.M., Bono F., Schaeffer P., Casellas P., Bourie B., Pili R., Isaacs J., Ator M., Hudkins R., Vaught J., Mallamo J., and Dionne C. CEP-7055: a novel, orally active pan inhibitor of vascular endothelial growth factor receptor tyrosine kinases with potent antiangiogenic activity and antitumor efficacy in preclinical models. Cancer Res. 63 18 (2003) 5978-5991
110. Schacht V., Ramirez M.I., Hong Y.K., Hirakawa S., Feng D., Harvey N., Williams M., Dvorak A.M., Dvorak H.F., Oliver G., and Detmar M. T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO J. 22 14 (2003) 3546-3556
111. Schietroma C., Cianfarani F., Lacal P.M., Odorisio T., Orecchia A., Kanitakis J., D'Atri S., Failla C.M., and Zambruno G. Vascular endothelial growth factor-C expression correlates with lymph node localization of human melanoma metastases. Cancer 98 4 (2003) 789-797
112. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., Kriehuber E., Nagy K., Alitalo K., and Kerjaschki D. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am. J. Pathol. 161 3 (2002) 947-956
113. Sedivy R., Beck-Mannagetta J., Haverkampf C., Battistutti W., and Honigschnabl S. Expression of vascular endothelial growth factor-C correlates with the lymphatic microvessel density and the nodal status in oral squamous cell cancer. J. Oral Pathol. Med. 32 8 (2003) 455-460
114. Shimizu K., Kubo H., Yamaguchi K., Kawashima K., Ueda Y., Matsuo K., Awane M., Shimahara Y., Takabayashi A., Yamaoka Y., and Satoh S. Suppression of VEGFR-3 signaling inhibits lymph node metastasis in gastric cancer. Cancer Sci. 95 4 (2004) 328-333
115. Shintani S., Li C., Ishikawa T., Mihara M., Nakashiro K., and Hamakawa H. Expression of vascular endothelial growth factor A, B, C, and D in oral squamous cell carcinoma. Oral Oncol. 40 1 (2004) 13-20
116. Siegfried G., Basak A., Cromlish J.A., Benjannet S., Marcinkiewicz J., Chretien M., Seidah N.G., and Khatib A.M. The secretory proprotein convertases furin, PC5, and PC7 activate VEGF-C to induce tumorigenesis. J. Clin. Invest. 111 11 (2003) 1723-1732
117. Sipos B., Klapper W., Kruse M.L., Kalthoff H., Kerjaschki D., and Kloppel G. Expression of lymphangiogenic factors and evidence of intratumoral lymphangiogenesis in pancreatic endocrine tumors. Am. J. Pathol. 165 4 (2004) 1187-1197
118. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., and Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 7 2 (2001) 192-198
119. Sleeman J.P. The lymph node as a bridgehead in the metastatic dissemination of tumors. Recent Results Cancer Res. 157 (2000) 55-81
120. Sleeman J.P., Krishnan J., Kirkin V., and Baumann P. Markers for the lymphatic endothelium: in search of the holy grail?. Microsc. Res. Tech. 55 2 (2001) 61-69
121. Spliet W.G., Aronica E., Ramkema M., Witmer A.N., Schlingemann R.O., de Jong J.M., and Troost D. Immunohistochemical localization of vascular endothelial growth factor receptors-1, -2 and -3 in human spinal cord: altered expression in amyotrophic lateral sclerosis. Neuropathol. Appl. Neurobiol. 30 4 (2004) 351-359
122. Stacker S.A., Stenvers K., Caesar C., Vitali A., Domagala T., Nice E., Roufail S., Simpson R.J., Moritz R., Karpanen T., Alitalo K., and Achen M.G. Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers. J. Biol. Chem. 274 45 (1999) 32127-32136
123. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., and Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 7 2 (2001) 186-191
124. Stearns M.E., Wang M., Hu Y., Kim G., and Garcia F.U. Expression of a flt-4 (VEGFR3) splicing variant in primary human prostate tumors. VEGF D and flt-4t(Delta773-1081) overexpression is diagnostic for sentinel lymph node metastasis. Lab. Invest. 84 6 (2004) 785-795
125. Straume O., Jackson D.G., and Akslen L.A. Independent prognostic impact of lymphatic vessel density and presence of low-grade lymphangiogenesis in cutaneous melanoma. Clin. Cancer Res. 9 1 (2003) 250-256
126. Suzuki K., Morita T., and Tokue A. Vascular endothelial growth factor-C (VEGF-C) expression predicts lymph node metastasis of transitional cell carcinoma of the bladder. Int. J. Urol. 12 2 (2005) 152-158
127. Taipale J., Makinen T., Arighi E., Kukk E., Karkkainen M., and Alitalo K. Vascular endothelial growth factor receptor-3. Curr. Top. Microbiol. Immunol. 237 (1999) 85-96
128. Takahashi A., Kono K., Itakura J., Amemiya H., Feng Tang R., Iizuka H., Fujii H., and Matsumoto Y. Correlation of vascular endothelial growth factor-C expression with tumor-infiltrating dendritic cells in gastric cancer. Oncology 62 2 (2002) 121-127
129. Takeuchi H., Bilchik A., Saha S., Turner R., Wiese D., Tanaka M., Kuo C., Wang H.J., and Hoon D.S. c-MET expression level in primary colon cancer: a predictor of tumor invasion and lymph node metastases. Clin. Cancer Res. 9 4 (2003) 1480-1488
130. Tang R.F., Itakura J., Aikawa T., Matsuda K., Fujii H., Korc M., and Matsumoto Y. Overexpression of lymphangiogenic growth factor VEGF-C in human pancreatic cancer. Pancreas 22 3 (2001) 285-292
131. Tanigaki Y., Nagashima Y., Kitamura Y., Matsuda H., Mikami Y., and Tsukuda M. The expression of vascular endothelial growth factor-A and -C, and receptors 1 and 3: correlation with lymph node metastasis and prognosis in tongue squamous cell carcinoma. Int. J. Mol. Med. 14 3 (2004) 389-395
132. Tarin D., Price J.E., Kettlewell M.G., Souter R.G., Vass A.C., and Crossley B. Mechanisms of human tumor metastasis studied in patients with peritoneovenous shunts. Cancer Res. 44 8 (1984) 3584-3592
133. Trikha M., and Nakada M.T. Platelets and cancer: implications for antiangiogenic therapy. Semin. Thromb. Hemost. 28 1 (2002) 39-44
134. Trojan L., Michel M.S., Rensch F., Jackson D.G., Alken P., and Grobholz R. Lymph and blood vessel architecture in benign and malignant prostatic tissue: lack of lymphangiogenesis in prostate carcinoma assessed with novel lymphatic marker lymphatic vessel endothelial hyaluronan receptor (LYVE-1). J. Urol. 172 1 (2004) 103-107
135. Tsurusaki T., Kanda S., Sakai H., Kanetake H., Saito Y., Alitalo K., and Koji T. Vascular endothelial growth factor-C expression in human prostatic carcinoma and its relationship to lymph node metastasis. Br. J. Cancer 80 1-2 (1999) 309-313
136. Tsutsumi S., Kuwano H., Shimura T., Morinaga N., Mochiki E., and Asao T. Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer. Hepatogastroenterology 52 62 (2005) 629-632
137. Ueda M., Terai Y., Yamashita Y., Kumagai K., Ueki K., Yamaguchi H., Akise D., Hung Y.C., and Ueki M. Correlation between vascular endothelial growth factor-C expression and invasion phenotype in cervical carcinomas. Int. J. Cancer 98 3 (2002) 335-343
138. Ueda M., Hung Y.C., Terai Y., Kanda K., Kanemura M., Futakuchi H., Yamaguchi H., Akise D., Yasuda M., and Ueki M. Vascular endothelial growth factor-C expression and invasive phenotype in ovarian carcinomas. Clin. Cancer Res. 11 9 (2005) 3225-3232
139. Van Trappen P.O., Steele D., Lowe D.G., Baithun S., Beasley N., Thiele W., Weich H., Krishnan J., Shepherd J.H., Pepper M.S., Jackson D.G., Sleeman J.P., and Jacobs I.J. Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D, and their receptor VEGFR-3, during different stages of cervical carcinogenesis. J. Pathol. 201 4 (2003) 544-554
140. Veikkola T., Jussila L., Makinen T., Karpanen T., Jeltsch M., Petrova T.V., Kubo H., Thurston G., McDonald D.M., Achen M.G., Stacker S.A., and Alitalo K. Signalling via vascular endothelial growth factor receptor-3 is sufficient for lymphangiogenesis in transgenic mice. EMBO J. 20 6 (2001) 1223-1231
141. Veronesi U., Luini A., Galimberti V., and Zurrida S. The dissection of internal mammary nodes does not improve the survival of breast cancer patients. Eur. J. Cancer 35 1 (1999) 1320-1325
142. Vlahakis N.E., Young B.A., Atakilit A., and Sheppard D. The lymphangiogenic vascular endothelial growth factors VEGF-C and -D are ligands for the integrin alpha9beta1. J. Biol. Chem. 280 6 (2005) 4544-4552
143. Vleugel M.M., Bos R., van der Groep P., Greijer A.E., Shvarts A., Stel H.V., van der Wall E., and van Diest P.J. Lack of lymphangiogenesis during breast carcinogenesis. J. Clin. Pathol. 57 7 (2004) 746-751
144. Wartiovaara U., Salven P., Mikkola H., Lassila R., Kaukonen J., Joukov V., Orpana A., Ristimaki A., Heikinheimo M., Joensuu H., Alitalo K., and Palotie A. Peripheral blood platelets express VEGF-C and VEGF which are released during platelet activation. Thromb. Haemost. 80 1 (1998) 171-175
145. White J.D., Hewett P.W., Kosuge D., McCulloch T., Enholm B.C., Carmichael J., and Murray J.C. Vascular endothelial growth factor-D expression is an independent prognostic marker for survival in colorectal carcinoma. Cancer Res. 62 6 (2002) 1669-1675
146. Wigle J.T., and Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell 98 6 (1999) 769-778
147. Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., and Trail P.A. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64 19 (2004) 7099-7109
148. Witmer A.N., Blaauwgeers H.G., Weich H.A., Alitalo K., Vrensen G.F., and Schlingemann R.O. Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF-induced retinopathy in monkey. Invest. Ophthalmol. Vis. Sci. 43 3 (2002) 849-857
149. Witmer A.N., Dai J., Weich H.A., Vrensen G.F., and Schlingemann R.O. Expression of vascular endothelial growth factor receptors 1, 2, and 3 in quiescent endothelia. J. Histochem. Cytochem. 50 6 (2002) 767-777
150. Witzenbichler B., Asahara T., Murohara T., Silver M., Spyridopoulos I., Magner M., Principe N., Kearney M., Hu J.S., and Isner J.M. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am. J. Pathol. 153 2 (1998) 381-394
151. Xu T., Chen D., and Chen J. Expression of vascular endothelial growth factor C and its correlation with lymph node metastasis in colorectal carcinoma. J. Huazhong Univ. Sci. Technolog. Med. Sci. 24 6 (2004) 596-598
152. Yan C., Zhu Z.G., Yu Y.Y., Ji J., Zhang Y., Ji Y.B., Yan M., Chen J., Liu B.Y., Yin H.R., and Lin Y.Z. Expression of vascular endothelial growth factor C and chemokine receptor CCR7 in gastric carcinoma and their values in predicting lymph node metastasis. World J. Gastroenterol. 10 6 (2004) 783-790
153. Yanai Y., Furuhata T., Kimura Y., Yamaguchi K., Yasoshima T., Mitaka T., Mochizuki Y., and Hirata K. Vascular endothelial growth factor C promotes human gastric carcinoma lymph node metastasis in mice. J. Exp. Clin. Cancer Res. 20 (2001) 419-428
154. Yang W., Klos K., Yang Y., Smith T.L., Shi D., and Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer 94 11 (2002) 2855-2861
155. Yasuoka H., Nakamura Y., Zuo H., Tang W., Takamura Y., Miyauchi A., Nakamura M., Mori I., and Kakudo K. VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma. Mod. Pathol. 18 8 (2005) 1127-1133
156. Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., Emoto M., Sakamoto A., Sakamoto T., Maruyama H., Sato S., Mizunuma H., and Smith S.K. Expression of vascular endothelial growth factor (VEGF)-D and its receptor, VEGF receptor 3, as a prognostic factor in endometrial carcinoma. Clin. Cancer Res. 9 4 (2003) 1361-1369
157. Yokoyama Y., Charnock-Jones D.S., Licence D., Yanaihara A., Hastings J.M., Holland C.M., Emoto M., Umemoto M., Sakamoto T., Sato S., Mizunuma H., and Smith S.K. Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma. Br. J. Cancer 88 2 (2003) 237-244
158. Yonemura Y., Endo Y., Fujita H., Fushida S., Ninomiya I., Bandou E., Taniguchi K., Miwa K., Ohoyama S., Sugiyama K., and Sasaki T. Role of vascular endothelial growth factor C expression in the development of lymph node metastasis in gastric cancer. Clin. Cancer Res. 5 7 (1999) 1823-1829
159. Zeng Y., Opeskin K., Horvath L.G., Sutherland R.L., and Williams E.D. Lymphatic vessel density and lymph node metastasis in prostate cancer. Prostate 65 3 (2005) 222-230